Article
The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The pharmacogenomics journal - 1 Jun 2021
Khushman Moh'd, Patel Girijesh Kumar, Maharjan Anu Singh, McMillin Gwendolyn A, Nelson Cindy, Hosein Peter, Singh Ajay P
Abstract excerpt
INTRODUCTION: The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predicting severe fluoropyrimidine-related adverse events (FrAE) is controversial. Here, we explored the prevalence and clinical relevance of 2R/2R TYMS genotype. METHODS: Between 2011 and 2018, 126 patients were genotyped for TYMS. FrAEs were graded...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.